Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) has shared an update.
Immunovia AB is set to release its second quarter 2025 results on August 28, 2025, and will host a webcast teleconference to discuss the company’s developments, including the upcoming launch of the PancreaSure test. This announcement highlights Immunovia’s ongoing efforts to enhance its market position in pancreatic cancer diagnostics, potentially benefiting stakeholders by advancing early detection solutions.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing simple tests to detect proteins and blood-based antibodies indicating pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, experts, and patient advocacy groups to make its tests accessible, with the USA being its largest market.
YTD Price Performance: 28.21%
Average Trading Volume: 7,445,177
Technical Sentiment Signal: Hold
Current Market Cap: SEK214.3M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.